Title : revolution in nanotherapeutics for treatment and management of high grade glioblastoma Multiform
Abstract:
Intracranial malignancies represent 1.4% of diagnosed cancers and Glioblastoma multiform (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Globally it counts the 3.5 cases per 100000 people every year. The cancerous tissues invade the surrounding cells making it impossible to cure surgically. Moreover, GBM is amongst the most resistant to chemotherapy and radiation. Currently, there are no curative treatment options available for GBM, and despite rigorous therapeutic research. Only few approved drugs are available for the treatment of GBM that includes DNA alkylators, kinase inhibitors and tubulin inhibitors that too are not effective to fill this gap successfully for management of GBM. The effective and safe delivery of drug candidate at the target site is quite challenging in GBM because of complexity of BBB, insufficient bioavailability of chemotherapeutic agent at tumor site due to physico-chemical nature of active moieties, poor absorption, low oral bioavailability and high protein binding, short half-life resulting in insufficient delivery of current conventional chemotherapeutics which proves challenges in the therapeutic management of the disease.
To overcome current modalities nanotherapeutics has emerged as a novel tool in the management of GBM. Nanotherapeutics proves superior over traditional drug delivery techniques as they offer more safety, enhanced biocompatibility and effective site specific targeting with reduced off-target toxicities which may prove breakthrough in neuronal oncology treatment. Different nanostructured drug deliveries includes polymeric functionalized nanoparticles, solid-lipid nanoparticles, liposomes, hybrid vesicles, dendrimers, nanogels, nanorods, and nanowires have been developed for the effective treatment and diagnosis of GBM. Present talk will give insights on molecular pathology and triggering factors of GBM, various innovations in theranostics nanotherapeutics and advancement in the noninvasive targeting of GBM for combatting GBM.
